More articles from Original Article

Open Access
Potential treatment approaches for malignant peritoneal mesothelioma: in vivo and in vitro experimental study of natural killer cell immunotherapy
Heliang Wu, Yi Wang, Yulin Lin, Ru Ma, Xuemei Du, Yandong Su, Rui Yang, Zhiran Yang, Xinli Liang, Yinguang Zhang, Xiaoqing Liang, Zhonghe Ji, Chunning Lai, Yajing Huang and Yan Li

Cancer Biology & Medicine November 2024, 21 (11) 1078-1094; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0218
Open Access
MicroRNA-384 radiosensitizes human non-small cell lung cancer by impairing DNA damage response and repair signaling, which is inhibited by NF-κB
Yanchen Sun, Jing Wang, Minghan Qiu, Jinlin Zhao, Fangdi Zou, Maobin Meng, Xiangli Jiang, Zhiyong Yuan, Zeyun Mi and Zhiqiang Wu

Cancer Biology & Medicine November 2024, 21 (11) 1050-1066; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0146
Open Access
From complexity to clarity: development of CHM-FIEFP for predicting effective components in Chinese herbal formulas by using big data
Boyu Pan, Han Zhu, Jiaqi Yang, Liangjiao Wang, Zizhen Chen, Jian Ma, Bo Zhang, Zhanyu Pan, Guoguang Ying, Shao Li and Liren Liu

Cancer Biology & Medicine November 2024, 21 (11) 1067-1077; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0442
Open Access
Amplifying colorectal cancer progression: impact of a PDIA4/SP1 positive feedback loop by circPDIA4 sponging miR-9-5p
Yan Zhuang, Yiding Ai, Peng Li, Xin Yue, Yue Li, Luling Shan, Tongtong Wang, Peng Zhao and Xun Jin

Cancer Biology & Medicine October 2024, 21 (10) 916-933; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0112
Open Access
Clinical benefit and safety profile of cross-line therapy with CDK4/6 inhibitors: a retrospective study of HR+/HER2– advanced breast cancer
Qi Zhao, Mingxia Jiang, Jiaxuan Liu, Mengqi Zhang, Maiyue He, Shihan Zhou, Jiani Wang, Hongnan Mo, Bo Lan, Peng Yuan, Pin Zhang, Fei Ma, Qiao Li and Binghe Xu

Cancer Biology & Medicine October 2024, 21 (10) 934-950; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0204
Open Access
Enhancement of anti-PD-L1 antibody plus anlotinib efficacy due to downregulation of PD-L1 in the micro-conduit endothelium within the tumor: a randomized double-blind trial
Cuicui Zhang, Tianqing Chu, Qiming Wang, Ying Cheng, Yongxiang Zhang, Ruili Wang, Leilei Ma, Chaonan Qian, Baohui Han and Kai Li

Cancer Biology & Medicine October 2024, 21 (10) 951-962; DOI: https://doi.org/10.20892/j.issn.2095-3941.2023.0423
Open Access
Impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of immunotherapy in patients with chronic hepatitis B-related hepatocellular carcinoma
Jiaxin Han, Wentao Kuai, Liu Yang, Xuemei Tao, Yuekui Wang, Minghui Zeng, Yuqin Li, Yuqiang Mi, Ningning Zhang, Wei Lu and Liang Xu

Cancer Biology & Medicine September 2024, 21 (9) 813-825; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0048
Open Access
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer
Xiuzhi Zhu, Xiaohan Ying, Yin Liu, Yunyi Wang, Li Chen, Zhiming Shao, Xi Jin, Yizhou Jiang and Zhonghua Wang

Cancer Biology & Medicine September 2024, 21 (9) 784-798; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0009
Open Access
Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study
Yuxiao Liu, Xiaofan Guo, Peijun Xu, Yuning Song, Jing Huang, Xingyun Chen, Wenbo Zhu, Jihui Hao and Song Gao

Cancer Biology & Medicine September 2024, 21 (9) 799-812; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0036
Open Access
Multiple myeloma survival in New South Wales, Australia, by treatment era to 2020
Eleonora Feletto, Qingwei Luo, Anna Kelly, Marianne Weber, David Goldsbury, Katherine Barron, Karen Canfell and Xue Qin Yu

Cancer Biology & Medicine August 2024, 21 (8) 703-711; DOI: https://doi.org/10.20892/j.issn.2095-3941.2024.0177

Main menu

User menu

Search

More articles from Original Article

Pages

Navigate

More Information

For Authors

Journal Services